Dyne Therapeutics, Inc.

NasdaqGS:DYN Stock Report

Market Cap: US$2.5b

Dyne Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:DYN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Dec 24SellUS$3,988,016Forbion Capital Partners B.V.Company136,112US$29.34
05 Dec 24SellUS$4,079,361Forbion Capital Partners B.V.Company138,845US$29.39
03 Dec 24SellUS$3,273,008Forbion Capital Partners B.V.Company110,933US$30.37
14 Nov 24SellUS$293,050Forbion Capital Partners B.V.Company8,929US$32.82
14 Nov 24SellUS$25,884Atlas Venture L.P.Company782US$33.10
06 Sep 24SellUS$309,248Richard ScalzoIndividual9,596US$32.63
04 Sep 24BuyUS$1,057,216John CoxIndividual32,000US$33.09
11 Mar 24SellUS$223,465Joshua BrummIndividual8,618US$25.93
08 Mar 24SellUS$725,344Susanna HighIndividual27,199US$27.41
01 Mar 24SellUS$513,825Atlas Venture L.P.Company17,099US$30.05
28 Feb 24SellUS$2,166,797Atlas Venture L.P.Company89,407US$25.25
23 Feb 24SellUS$848,662Atlas Venture L.P.Company37,386US$22.70
09 Jan 24BuyUS$29,999,988Forbion Capital Partners B.V.Company1,714,285US$17.50

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of DYN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders312,5580.278%
Hedge Funds6,818,6416.07%
VC/PE Firms19,863,34417.7%
Institutions85,366,43576%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.6%.

Top Shareholders

Top 25 shareholders own 88.76% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
8.87%
FMR LLC
9,026,696US$223.5m69.7%0.01%
7.88%
Atlas Venture L.P.
8,019,354US$198.6m-0.01%24.02%
7.66%
BlackRock, Inc.
7,794,114US$193.0m5.51%no data
6.75%
The Vanguard Group, Inc.
6,864,137US$170.0m45.5%no data
6.7%
RTW Investments, LP
6,818,641US$168.8m6.76%2.49%
6.69%
Janus Henderson Group plc
6,813,163US$168.7m47.4%0.07%
6.27%
RA Capital Management, L.P.
6,381,144US$158.0m5.49%2.02%
5.37%
Forbion Capital Partners B.V.
5,462,846US$135.3m-8.25%23.1%
3.58%
State Street Global Advisors, Inc.
3,641,859US$90.2m13.8%no data
3.23%
Deep Track Capital, LP
3,282,000US$81.3m-18%2.59%
2.89%
Citadel Advisors LLC
2,939,340US$72.8m-31.9%0.08%
2.6%
TCG Crossover Management, LLC
2,650,150US$65.6m0%6.11%
2.59%
T. Rowe Price Group, Inc.
2,636,293US$65.3m11.4%0.01%
2.36%
Adage Capital Management, L.P.
2,402,972US$59.5m-27.8%0.11%
2.14%
VR Adviser, LLC
2,173,913US$53.8m0%2.83%
1.95%
Holocene Advisors, LP
1,982,640US$49.1m-4.51%0.2%
1.83%
Geode Capital Management, LLC
1,859,413US$46.0m4.78%no data
1.32%
Jennison Associates LLC
1,346,952US$33.4m1.49%0.02%
1.29%
Franklin Resources, Inc.
1,316,885US$32.6m-21.9%0.01%
1.24%
First Light Asset Management, LLC
1,257,285US$31.1m229%2.86%
1.2%
Federated Hermes, Inc.
1,217,170US$30.1m0.17%0.08%
1.14%
Armistice Capital LLC
1,155,204US$28.6m19%0.71%
1.11%
Artal Group S.A.
1,134,664US$28.1m-25.2%0.87%
1.1%
Vivo Capital, LLC
1,114,960US$27.6m-31.8%2.35%
1.01%
Morgan Stanley, Investment Banking and Brokerage Investments
1,030,688US$25.5m105%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 07:57
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dyne Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Keay NakaeChardan Capital Markets, LLC
Debjit ChattopadhyayGuggenheim Securities, LLC